U.S. FDA Warning Letters To Foreign Manufacturing Facilities Rise Dramatically
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA's device center is sending a record number of warning letters to foreign facilities as the agency continues its efforts to more effectively oversee product manufacturing located outside the U.S
You may also be interested in...
U.S. FDA Long-Term Globalization Strategy Under Development
Coping with an increasingly global device and drug industry will require a paradigm shift that relies less on U.S. FDA's own staff and more on data and resource sharing with other countries, the agency says
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).